Semaglutide-associated bullous pemphigoid

Burruss, Clayton Prakash; Jones, Jeffrey S.; Burruss, Jyoti B.

doi:10.1016/j.jdcr.2021.07.027

Cited by 12 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…observed a case developed one month after the introduction of semaglutide. 6 Instead, Collins et al . described a case of BP liraglutide-induced that occurred two weeks after the introduction.…”

Section: Discussionmentioning

confidence: 99%

“…5 In addition, Clayton et al observed a case developed one month after the introduction of semaglutide. 6 Instead, Collins et al described a case of BP liraglutide-induced that occurred two weeks after the introduction. 7 These reports seem to confirm that GLP-1 analogs can trigger BP, with latency from 2 weeks up to 2 months after the introduction of the therapy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Bullous pemphigoid triggered by dulaglutide: a case report and a review of the literature

Sonego,

Zelin,

Zalaudek

et al. 2023

Dermatol Reports

View full text Add to dashboard Cite

Bullous pemphigoid (BP) is an autoimmune disease with a chronic relapsing course, predominantly affecting elderly people. Drugs are one of the possible triggers. A class of antidiabetic drugs often associated with the development of BP are inhibitors of dipeptidyl peptidase 4 (DPP-4 inhibitors or gliptins), while less known is the association with glucagon-like-peptide-1 (GLP-1) receptor agonists. We describe a case of BP caused by dulaglutide and summarize the other few cases described in the literature. As a class of drugs widely used in clinical practice, it is important to know about this possible adverse event.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Bullous pemphigoid triggered by dulaglutide: a case report and a review of the literature

Sonego,

Zelin,

Zalaudek

et al. 2023

Dermatol Reports

View full text Add to dashboard Cite

show abstract

“…A presumed association between BP and glucagon-like peptide-1 (GLP-1) receptor agonists has also been reported [5].…”

mentioning

confidence: 95%

“…A presumed association between BP and glucagon-like peptide-1 (GLP-1) receptor agonists has also been reported [ 5 ]. The underlying mechanism is unclear, however since DPP4i and GLP-1 receptor agonists both rely on enhancing the activity of the incretin hormone GLP-1, a common effect between these two classes of antidiabetic drugs should be sought.…”

mentioning

confidence: 99%